Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of April 19th – 25th, 2021.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
Canopy Growth, Canada’s Largest Cannabis Licensed Producer Appears Set to for Another Major Growth Spurt Following the Company’s Suprise Announcement That it Would Be Acquiring Rival LP Supreme Cannabis
Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) announced recently that it would be acquiring Supreme Cannabis (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) for a cool $435 million. It’s a somewhat curious move, as Canopy Growth has been divesting, not acquiring, Canadian assets recently. Reaction from investors has been muted, as the stock price has not seen a large swing in either direction since the deal was announced.
Following the Revocation of the Cease Trade Orders and the CSE’s Acceptance of Champignon’s New Listing Statement, the Company’s Common Shares Recommenced Trading on the CSE
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced that the British Columbia Securities Commission and Ontario Securities Commission revoked their cease trade orders against the company effective April 22, 2021. “We are pleased to be moving forward with a strengthened team and focus on governance. We have successfully advanced our business strategy to establish a network of clinics designed to provide rapid-acting treatments for adults with depression,” said Dr. Roger McIntyre, Chairman and CEO. “Depression is known to be one of the most disabling conditions across Canada and around the world. In addition, we have also been able to advance our research and development towards discovering novel drug treatments for individuals affected by depression.”
Stock Warrants Function in Much the Same Way That Stock Options Do, Giving the Owner the Right to Buy or Sell Shares of a Company at a Specific Price
Where options and warrants defer is where the money goes when the contract is exercised. While options trade on exchanges and all the money is going between investors, shares associated with warrants will be newly issued by the company. So warrants provide the company with additional funding sources when exercised, while investors reap the reward of buying additional discounted shares. If the warrants are being exercised, it’s usually a win-win situation, as the company’s share price has usually risen a significant amount (and they get the cash). The investor makes a nice gain on their investment. Let’s take a closer look at the warrants of top U.S. Multi-State Operators (MSOs) Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), Cresco Labs (CSE: CL) (OTCQX: CRLBF), Ayr Strategies (CSE: AYR.A) (OTCQX: AYRSF) and Trulieve (CSE: TRUL) (OTCQX: TCNNF).
It’s No Secret That 2020 Was a Turning Point for Psychedelic Stocks in the Eyes of Investors and the Pandemic Has Precipitated a Heightened Focus on Mental Health and the Inadequacies of Our Current Standards of Care
The psychedelics market is on track to keep commanding investor attention this year. However, companies must continue delivering results and proving their worth with various mental health conditions. The first listing of a psychedelic pharmaceutical company was a landmark event for the industry in 2020. According to research, the industry is expected to grow at a massive 15.8% from 2020 to 2027. With that being said, let’s look at three of the top psychedelics that are making waves at this time.
- Compass Pathways (NASDAQ: CMPS)
- MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ)
- Numinus Wellness (TSXV: NUMI) (OTC: LKYSD) (FRA: LR23)
In the Update, Raymond James Analyst Rahul Sarugaser Maintained His “Outperform 2” Rating and $11 CRON Target Price
Cronos Group (TSX: CRON) (NASDAQ: CRON) (FRA: 7CI) saw its share price spike earlier this year, but the stock has now been on a prolonged slide since mid-February. Is there upside from here? Likely, says Raymond James analyst Rahul Sarugaser, who in a Friday client report previewed the company’s upcoming quarterly release, saying Cronos’ cannabinoid biosynthesis investments are about to pay off.
Approximately 5.8% or 14.4 Million Adults in the United States Ages 18 and Older Suffered From Alcohol Use Disorder in 2018
Cybin (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected Alcohol Use Disorder (AUD) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences.
The Company Will Tap into Southern Glazer’s Established Distribution Network to Bring Quatreau its CBD-Infused Sparkling Water, to U.S. Retailers
Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) announced Southern Glazer’s Wine & Spirits, the world’s pre-eminent distributor of beverage alcohol, as the distribution partner for its U.S. portfolio of CBD-infused beverages. This partnership announcement follows the recent launch of Quatreau – Canopy’s first line of CBD-infused beverages sold in the U.S market.
The Clinical Trial Will Evaluate the Safety and Psychoactive Properties of Natural Psilocybin Product Extracted and Formulated at the Company’s 7,000-Square-Foot Laboratory in British Columbia, Canada
Numinus Wellness (TSXV: NUMI) (OTC: LKYSD) (FRA: LR23), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that it has formed a partnership with KGK Science, a leading contract research organization with expertise in natural products, to undertake a new Psilocybin extraction clinical trial.
The U.S. is the Market to Be in, and There’s One Easy Way to Buy All the Most Promising Pot Stocks
The U.S. is the market investors should hang their hat on. Already, numbers here are crushing it in terms of both growth and revenue. What’s more amazing is cannabis isn’t even federally legal yet. There is plenty of upside still to be had. These results can be seen in the recent quarterly earnings from a top name, Cresco Labs (CSE: CL) (OTCQX: CRLBF). These are numbers Canadian Licensed Producers (LPs) can only dream about. Other leading U.S Multi-State Operators (MSOs) include Curaleaf (CSE: CURA) (OTCQX: CURLF), Ayr Strategies (CSE: AYR.A) (OTCQX: AYRSF), and Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2). The fact these companies can’t list on the NASDAQ or NYSE is a disgrace, but I digress; therefore, the simplest approach is to buy the AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS).
Per Company CEO J.R. Rahn, MindMed’s Mission is “to Discover, Develop and Deploy Psychedelic Inspired Medicines and Therapies to Address Addiction and Mental Illness”
Clinical-stage Psychedelic medicine and biotech company MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ) is surging again Monday ahead of its NASDAQ debut. MindMed announced last Friday it will be uplisted to the NASDAQ on Tuesday, leading to a 40% rise in share price.